Zymeworks Inc. (NYSE:ZYME) Shares Bought by Fmr LLC

Fmr LLC grew its position in Zymeworks Inc. (NYSE:ZYME) by 84.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,336 shares of the company’s stock after purchasing an additional 1,525 shares during the period. Fmr LLC’s holdings in Zymeworks were worth $42,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Rubric Capital Management LP lifted its position in Zymeworks by 12.7% during the second quarter. Rubric Capital Management LP now owns 3,917,331 shares of the company’s stock valued at $33,336,000 after purchasing an additional 441,947 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Zymeworks by 0.8% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,945,491 shares of the company’s stock valued at $24,416,000 after buying an additional 14,604 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Zymeworks by 55.2% in the second quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company’s stock worth $14,192,000 after buying an additional 592,904 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Zymeworks by 127.5% during the second quarter. Dimensional Fund Advisors LP now owns 715,632 shares of the company’s stock worth $6,090,000 after acquiring an additional 401,068 shares during the period. Finally, Monaco Asset Management SAM raised its position in Zymeworks by 15.0% during the second quarter. Monaco Asset Management SAM now owns 336,344 shares of the company’s stock valued at $2,862,000 after acquiring an additional 43,844 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ZYME shares. JPMorgan Chase & Co. raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective on the stock in a research note on Monday, December 16th. Wells Fargo & Company raised their price target on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research report on Thursday, December 19th. Leerink Partners upgraded shares of Zymeworks from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $10.00 to $25.00 in a research report on Thursday, November 7th. HC Wainwright restated a “neutral” rating and set a $12.00 target price on shares of Zymeworks in a research report on Friday, November 22nd. Finally, Stifel Nicolaus upped their price target on Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, October 28th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.17.

Zymeworks Stock Down 1.0 %

ZYME stock opened at $14.14 on Thursday. The stock has a market capitalization of $973.93 million, a P/E ratio of -9.43 and a beta of 1.12. Zymeworks Inc. has a 52 week low of $7.97 and a 52 week high of $17.70. The firm has a 50-day simple moving average of $14.23 and a 200-day simple moving average of $11.98.

Zymeworks (NYSE:ZYME) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. The company had revenue of $16.00 million during the quarter, compared to analyst estimates of $17.90 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. Zymeworks’s quarterly revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.41) EPS. On average, analysts expect that Zymeworks Inc. will post -1.43 earnings per share for the current year.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.